GENERAL
Cipla Gets US FDA Nod For Generic Advair Diskus; Scales COPD Portfolio
Drugmaker Cipla Ltd has received approval from the US Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for the generic version of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in all three dosage strengths. The approval covers 100/50 mcg, 250/50 mcg and 500/50 mcg strengths. The product is therapeutically […]
CW Bureau
·
Jul 28, 2026
GENERAL
Cipla Bets On Innovation, Biosimilars And AI To Drive Next Phase Of Growth
Cipla Ltd, the Mumbai-headquartered global pharmaceutical major, is stepping up investments in innovation, artificial intelligence, biosimilars and strategic acquisitions as it looks to strengthen its position across key global markets and build a future-ready organisation. India will remain a key growth driver, with the company focusing on therapy areas including respiratory, cardiology, diabetology, urology, oncology, […]
CW Bureau
·
Jun 2, 2026
GENERAL
After 90 Years Of ‘Caring For Life’, Cipla Charts Innovative Journey Path
Ninety years ago, Mumbai headquartered Cipla Ltd, began with a mission to make medicines affordable and accessible for Indians. What started as a commitment to self-reliance in pharmaceuticals has evolved into a global healthcare enterprise serving millions of patients across markets. As Cipla celebrates 90 years of its journey, the company is looking ahead with […]
CW Bureau
·
Jun 2, 2026
HOSPITALITY
Cipla To Invest $100-Mn In Cipla (EU); To Merge Inzpera Healthsciences
Leading global pharmaceutical company Cipla Ltd approved an investment of $100 million in its wholly owned subsidiary Cipla (EU) and amalgamation of Inzpera Healthsciences Ltd with itself. In a regulatory filing, Cipla said that the investment of $100 million in Cipla (EU) will be utilised for onward financial assistance to InvaGen Pharmaceuticals Inc. towards capital […]
CW Bureau
·
Mar 20, 2026
